Localized Scleroderma research hub

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)

This study looks at a new medicine called lebrikizumab for people with localised scleroderma. Researchers want to see if it's safe and helps improve skin symptoms. Half the people will get the new medicine, and half will get a dummy medicine, without knowing which one they have.